At the data cut-off time (January 11, 2022), the median follow-up was 15.2months. Among enrolled patients, twelve cases had EGFR Ex20ins and remaining nine cases had EGFR other mutations such as L861Q, G719A, and G709T. Patients harboring uncommon EGFR mutations exhibited a median progression-free survival of6.7 months (95% CI, 2.4, 11.0), and the 6-month PFS rate was 52.4%. Moreover, of the nineteen patients evaluable for efficacy, the objective response rate (ORR) was 36.8%(7/19), and the disease control rates (DCR) was 84.2% (16/19). Notably, patients carrying EGFR Ex20ins showed similar ORR/DCR and PFS with other mutation patterns(ORR: 36.4% [4/11] vs. 37.5% [3/8], p¼1.00; DCR: 90.9% [10/11] vs. 75.0% [6/8],p¼0.348, PFS: 4.3 vs. 7.1 months, p¼0.327).Combination of sintilimab and anlotinib demonstrated durable efficacy and good tolerability in NSCLC patients with uncommon EGFR mutations. And further investigate is warranted to confirm this new chemo-free strategy.